Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) have been assigned a consensus rating of “Buy” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $12.38.
Separately, HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Corvus Pharmaceuticals in a report on Tuesday, January 14th.
View Our Latest Stock Report on CRVS
Hedge Funds Weigh In On Corvus Pharmaceuticals
Corvus Pharmaceuticals Stock Performance
Shares of NASDAQ CRVS opened at $4.72 on Tuesday. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00. The stock’s 50-day simple moving average is $4.84 and its 200-day simple moving average is $6.09. The firm has a market cap of $303.29 million, a price-to-earnings ratio of -5.08 and a beta of 0.91.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.
Further Reading
- Five stocks we like better than Corvus Pharmaceuticals
- Are Penny Stocks a Good Fit for Your Portfolio?
- Can TikTok Stock Picks Really Make You Rich?
- What is a Stock Market Index and How Do You Use Them?
- The “Quality” Rotation: Back to Basics Investing
- The Role Economic Reports Play in a Successful Investment Strategy
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.